Astatine-211 targets blood-borne cancers in Seattle clinical trials

September 13, 2022, 9:30AMNuclear News
A clinical dose of At-211 is prepared at the University of Washington for use in a Fred Hutchison Cancer Center clinical trial. (Photo: UW/Don Hamlin)

Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

To continue reading, log in or create a free account!

Related Articles

DOE secretary testifies on FY 2027 budget

April 22, 2026, 10:40AMNuclear News

Energy Secretary Chris Wright has spent the past week courting members of Congress to approve his agency’s $53.9 billion discretionary budget request for fiscal year 2027. On Tuesday, Wright...

CEO and CFO of Fermi America step down

April 22, 2026, 7:56AMNuclear News

On Friday, two of the four cofounders at Fermi America unexpectedly exited their roles at the company. Those were Toby Neugebauer, former CEO and chairman of the board of directors, and Miles...

Beyond the grid

April 21, 2026, 11:54AMNuclear NewsCraig Piercy

In this month’s issue of Nuclear News, readers will find coverage of the “other” areas where nuclear technology is pushing into new frontiers. From marine nuclear propulsion to nuclear...

OSTP memo guides space nuclear plan

April 16, 2026, 12:00PMNuclear News

A White House Office of Science and Technology Policy (OSTP) memorandum released on Tuesday guides NASA, the Department of Energy, and the Department of Defense on their roles in deploying...